Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

Autor Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
Vydáno v Arthritis Res Ther (2015)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'

Autor Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, Vastesaeger, Nathan, Geldhof, Anja, De Keyser, Filip
Vydáno 2006

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

Autor Baranauskaite, Asta, Raffayová, Helena, Kungurov, NV, Kubanova, Anna, Venalis, Algirdas, Helmle, Laszlo, Srinivasan, Shankar, Nasonov, Evgeny, Vastesaeger, Nathan
Vydáno 2011

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

Autor Bruges-Armas, Jácome, Bettencourt, Bruno F., Couto, Ana R., Lima, Manuela, Rodrigues, Ana M., Vastesaeger, Nathan, Brown, Matthew A.
Vydáno v Case Rep Rheumatol (2014)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice

Autor Cruyssen, Bert Vander, Ribbens, Clio, Boonen, Annelies, Mielants, Herman, de Vlam, Kurt, Lenaerts, Jan, Steinfeld, Serge, Van den Bosch, Filip, Dewulf, Lode, Vastesaeger, Nathan
Vydáno 2007

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

Autor Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
Vydáno 2014

Predicting the outcome of ankylosing spondylitis therapy

Autor Vastesaeger, Nathan, van der Heijde, Désirée, Inman, Robert D, Wang, Yanxin, Deodhar, Atul, Hsu, Benjamin, Rahman, Mahboob U, Dijkmans, Ben, Geusens, Piet, Vander Cruyssen, Bert, Collantes, Eduardo, Sieper, Joachim, Braun, Jürgen
Vydáno 2011

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Autor Cruyssen, Bert Vander, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Mielants, Herman, De Clerck, Luc, Peretz, Ann, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Vydáno 2006

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab...

Autor Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Veys, Eric M, Mielants, Herman, De Clerck, Luc, Peretz, Anne, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Vydáno 2005

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

Autor Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Lazaro, María Alicia, Moots, Robert J., Wollenhaupt, Jürgen, Zerbini, Cristiano A. F., Louw, Ingrid, Combe, Bernard, Beaulieu, Andre, Schulze-Koops, Hendrik, Dasgupta, Bhaskar, Fu, Bo, Huyck, Susan, Weng, Haoling H., Govoni, Marinella, Durez, Patrick
Vydáno v Rheumatology (Oxford) (2016)